Inhibrx trial data shows reduced tumors in mid-stage head and neck study
Inhibrx Biosciences said its experimental combination cancer drug reduced tumors in a mid-stage study of patients with a type of head and neck cancer. Shares were marginally up in premarket trading.
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer. Shares of the company were marginally higher in premarket trading.